Avacta’s cash runway of £16.4m at end-April 2026 extends into early Q127, beyond key catalysts for the two lead pre|CISION peptide-drug conjugate (PDC) assets, faridoxorubicin and AVA6103 (FAP-EXd). Cash resources have been boosted by the £32.5m in new equity raised over the last 18 months, most recently £10m gross in March 2026, enabling continued investment into the platform and PDC pipeline towards upcoming value inflection points.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.